An international team of leading scientists has developed a drug that could be an effective treatment for Alzheimer’s disease.
The drug, a small molecule called anle138b, has been tested in mice with a ‘genetic predisposition for developing’ the disease. And the results were more than promising, as the drug ‘normalized brain activity and improved learning ability in mice’.
“The drug is able to reach the brain when taken orally. Therefore, it is easy to administer, and we are currently performing toxicology studies to eventually be able to apply anle138b to humans,” said Christian Griesinger, a professor at the Max Planck Institute for Biophysical Chemistry.
The Institute was one of the bodies that led the study, along with the German Center for Neurodegenerative Diseases, the University Medical Center Göttingen, the Braunschweig University of Technology, the Center for Nanoscale Microscopy and Molecular Physiology of the Brain in Göttingen, Germany, and the University of California San Diego.
It is the latest potential game-changer in the fight Alzheimer’s. Innovators Magazine reported in October a therapy pioneered by M3 Biotechnology is undergoing clinical trials in America, which has shown signs it could ‘stop or slow’ the disease.
